- Home
- TRDA vs MGTX Comparison
TRDA vs MGTX Comparison
Compare TRDA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- MGTX
- Stock Information
- Founded
- TRDA 2016
- MGTX 2015
- Country
- TRDA United States
- MGTX United States
- Employees
- TRDA N/A
- MGTX N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRDA Health Care
- MGTX Health Care
- Exchange
- TRDA Nasdaq
- MGTX Nasdaq
- Market Cap
- TRDA 264.5M
- MGTX 622.0M
- IPO Year
- TRDA 2021
- MGTX N/A
- Fundamental
- Price
- TRDA $6.64
- MGTX $7.89
- Analyst Decision
- TRDA Strong Buy
- MGTX Strong Buy
- Analyst Count
- TRDA 3
- MGTX 2
- Target Price
- TRDA $25.67
- MGTX $24.00
- AVG Volume (30 Days)
- TRDA 127.9K
- MGTX 641.6K
- Earning Date
- TRDA 08-12-2025
- MGTX 08-11-2025
- Dividend Yield
- TRDA N/A
- MGTX N/A
- EPS Growth
- TRDA N/A
- MGTX N/A
- EPS
- TRDA 0.61
- MGTX N/A
- Revenue
- TRDA $172,220,000.00
- MGTX $34,508,000.00
- Revenue This Year
- TRDA N/A
- MGTX $228.65
- Revenue Next Year
- TRDA N/A
- MGTX $145.06
- P/E Ratio
- TRDA $10.80
- MGTX N/A
- Revenue Growth
- TRDA 5.74
- MGTX 203.23
- 52 Week Low
- TRDA $6.12
- MGTX $3.85
- 52 Week High
- TRDA $21.79
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- TRDA 47.73
- MGTX 51.03
- Support Level
- TRDA $6.18
- MGTX $8.32
- Resistance Level
- TRDA $6.67
- MGTX $8.52
- Average True Range (ATR)
- TRDA 0.34
- MGTX 0.38
- MACD
- TRDA 0.04
- MGTX -0.15
- Stochastic Oscillator
- TRDA 66.67
- MGTX 10.66
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.